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Background:  We  aimed  to  verify  a  measure  for functional  limitation  using  the Performance  Measure  for
Activity  of Daily  Living-8  (PMADL-8)  clinical  assessment  tool.  This  tool  was  utilized  to  determine  disease
severity  by  comparing  disease  severity  with  physiological  and  demographic  variables,  which  have  been
well documented  as  predictors  for mortality  and  rehospitalization  in chronic  heart  failure  (CHF)  patients.
Methods:  We  consecutively  enrolled  125  CHF  patients  with  impaired  left ventricular  systolic  function
who  underwent  cardiopulmonary  exercise  testing  in Nagoya  University  Hospital.  We  measured  PMADL-
8, which  had  a total  score  that ranged  from  8 to 32 points,  in  which  higher  scores  indicated  severe
functional  limitations  to evaluate  the patient’s  functional  limitations  and  evaluate  clinical physiologic
variables,  which  were  established  as prognostic  factors  of  CHF.  First,  the  association  between  PMADL-8
and  other  clinical  variables  was  analyzed  by  correlation  coefﬁcients,  and  then,  multivariate  regression
analysis  was performed  to  select  independent  correlate  factors.  Lastly,  we  identiﬁed  the  optimal  PMADL-
8 threshold  for detecting  disease  severity  by comparing  with  the  threshold  for disease  severity  in  selected
variables.
Results:  The  PMADL-8  indicated  excellent  correlation  with  peak  oxygen  uptake  (peakVO2)  (r  = −0.743,
p  < 0.001),  and  the  multivariate  regression  analysis  revealed  that  peakVO2 was  independently  corre-
lated  with  the  PMADL-8  (p <  0.001).  The  optimal  PMADL-8  threshold  for  detecting  a  peakVO2 value  of
18  ml/min/kg  was 18  points.  Similarly,  a  peakVO2 value  of  14  ml/min/kg  was  22 points,  and  a peakVO2
value  of  16 ml/min/kg  was  20 points.
Conclusions:  Our  data  indicate  that functional  limitation  as  evaluated  by  the PMADL-8  is  well  correlated
with  peakVO2. PMADL-8  may  have  potential  as  a clinical  assessment  tool  to  manage  disease  status  in
CHF  patients.
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Chronic heart failure (CHF) is a systemic and progressive dis-
ase characterized by functional limitations in daily activities that
re caused by clinical symptoms, shortness of breathing, or fatiga-
ility [1].  The New York Heart Association (NYHA) functional class
s the most well-known clinical marker for functional limitations in
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CHF patients and serves as a predictive marker of hospitalization,
disease progression, and mortality [2].
Despite the fact that the functional decline in CHF patients
reﬂects disease progression, evidence of functional limitations as a
predictive parameter for disease status has not been demonstrated.
This may  be, in part, due to the lack of an objective measurement
tool to evaluate functional limitations in CHF patients. Several ques-
tionnaires have been reported to measure functional limitations in
CHF patients [3,4], however, these questionnaires were originally
developed to measure health-related quality of life (HRQOL) or
health status. The factors of functional limitation that are contained
in these questionnaires have not been studied independently from
the viewpoint of CHF disease status.
Functional limitations manifest as difﬁculty in performing
daily activities. Functional limitations of CHF mostly arise from a
vier Ltd. All rights reserved.
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ombination of physical limitations and symptoms. Furthermore,
linical CHF symptoms are induced by disease-speciﬁc central and
eripheral abnormalities, such as cardiac dysfunction, hemody-
amic abnormalities, skeletal muscle abnormalities, and excessive
eurohormonal activation [5,6]. Therefore, a subjective measure
f functional limitations in CHF patients has the potential to be a
linical predictor for CHF disease severity. To examine this hypoth-
sis, we developed a self-reported, simple questionnaire known as
he Performance Measure for Activities of Daily Living-8 (PMADL-
) to assess functional limitations by measuring the difﬁculty in
erforming daily activities based on the Japanese CHF population
7].
In this study, we aimed to verify PMADL-8 as a clinical assess-
ent tool to determine disease severity by comparing the PMADL-8
core with physiological and demographic variables that have been
ocumented as predictors for mortality or rehospitalization in CHF
atients.
aterials and methods
tudy area and population
We studied 125 consecutive CHF patients with dilated car-
iomyopathy at Nagoya University Hospital between December
007 and August 2010. Patients who lacked motivation to par-
icipate in this study were excluded. All patients had a normal
inus rhythm and reduced left ventricular ejection fraction less
han 50%, and were on optimal pharmacological therapy, according
o the current guidelines for the treatment of HF [1].  No patients
ad implantable cardioverter-deﬁbrillators or pacemakers. Each
atient was a stable HF patient, underwent cardiopulmonary
xercise testing (CPX), laboratory measurements, and echocardio-
raphy and answered a self-reported questionnaire. The study
rotocol was approved by the Ethics Review Board of Nagoya
niversity School of Medicine (Approval No. 359), and written
nformed consent was obtained from all of the study subjects.
MADL-8
PMADL-8 is an 8-item, self-administered questionnaire that
uantiﬁes functional limitations in activity of daily living for
atients with HF. PMADL-8 was measured with a 4-category
esponse scale (i.e., 1 = very easy; 2 = somewhat easy; 3 = somewhat
ard; and 4 = very hard), which had a total score that ranged from
 to 32 points, in which higher scores indicated severe functional
imitations. The assessment tool had excellent internal consistency,
est–retest reliability and validity of hierarchical scale as assessed
y a Rasch scaling analysis in elderly Japanese CHF patients [7]. All
articipants completed the PMADL-8 assessment independently
ust before CPX was performed.
xercise testing
Each patient underwent CPX at a progressively increasing work
ate to maximum tolerance on a cycle ergometer. The test proto-
ol was in accordance with the recommendations of the American
ollege of Sports Medicine (ACSM) [8].  All patients began at 0 W
or a 3-min warm-up, which was followed by a 10 W/min  ramp
ncrement protocol up to the termination criteria [9].  The test ter-
ination criteria were determined according to the ACSM criteria.
 qualiﬁed exercise physiologist conducted each test with a physi-
ian’s supervision. A 12-lead electrocardiogram was monitored
ontinuously, and blood pressure was measured every minute
uring exercise and throughout the recovery period. Respiratory
as exchange variables, including oxygen uptake (VO2), carbon
ioxide production (VCO2), and minute ventilation (VE), werelogy 60 (2012) 411–415
acquired continuously throughout the exercise testing using an
Ergospirometry Oxycon Pro (Care Fusion; San Diego, CA, USA),
and gas-exchange data were obtained with each breath. Peak oxy-
gen uptake (peakVO2) and the minute ventilation/carbon dioxide
production slope (VE/VCO2 slope) were measured as indices of
physiologic outcome. The exercise physiologist was blinded to the
PMADL-8 scores.
According to American Thoracic Society guideline, the 6-min
walking test was performed indoors along a ﬂat, 100-m circular
corridor that had a hard surface [10].
Other parameter measurements
We  evaluated other prognostic variables to verify the validity
of PMADL-8 as a disease assessment tool. We  selected established
prognostic variables, including body mass index, plasma brain
natriuretic peptide level, serum hemoglobin, serum albumin, and
estimated glomerular ﬁltration rate from the results of a blood
investigation [11,12],  and we  obtained the left ventricular ejection
fraction (LVEF), E/Ea which was the ratio of the early transmitral
ﬂow velocity to the early diastolic mitral annular velocity from
echocardiography ﬁndings. Handgrip strength was  measured using
a Jamar dynamometer. The participants were asked to sit with
their wrist in a neutral position and elbow ﬂexed to 90◦ [13]. Grip
strength was  measured 3 times for each hand, and the highest value
was used for the analysis. Knee extensor muscle strength was mea-
sured using a digital hand-held dynamometer (m-Tas F1, Anima
Co., Chofu, Tokyo, Japan), which has been validated and shown to
be reliable among the elderly [14,15].  During testing, the partici-
pant adopted a dangling position with the arms held on the edge
of the table and was  then ﬁtted with a hand-held dynamometer on
the anterior aspect of the measured ankle, which was ﬁxed to the
table leg by a vinyl strap. The participants were asked to extend
their leg and push with maximal effort 2 times per leg. The lever
length was also measured from the lateral joint space of the knee
to the lateral top of the belt. The best performance was used as the
maximal power and was  transformed into Newton meters (Nm).
Statistical analysis
The data are presented as the mean ± standard deviation for the
continuous variables and percentages for the categorical data. First,
the association between PMADL-8 scores and the clinical variables
were analyzed by Pearson’s or Spearman’s correlation coefﬁcients.
Variables with a p-value less than 0.1 upon univariate analysis were
entered into the multivariate regression analysis with a stepwise
forward selection procedure to determine the independent factors
of PMADL-8. We  then identiﬁed the optimal PMADL-8 threshold for
detecting disease prognosis by comparing with selected variables.
All analyses were performed with the SPSS 16.0 software package
(SPSS Inc., Tokyo, Japan). A p-value of less than 0.05 was considered
statistically signiﬁcant.
Results
The baseline clinical patient characteristics are shown in Table 1.
The mean age was  57.6 years (range, 22–86 years) old, and 92% of
the patients were classiﬁed as NYHA functional class I or II and had
mild symptoms. The mean LVEF was  36.4% and 102 patients (81.6%)
had reduced LVEF which was less than 40%. Seventy-six patients
(64.0%) had been treated with angiotensin-converting enzyme
inhibitors and angiotensin II type 1 receptor blockers because some
patients started these medications after examination. No patients
had abnormal respiratory function or severe pulmonary hyperten-
sion.
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Table  1
Patient demographics and clinical characteristics.
Total (n = 125)
Age (yo) 56.8 (14.1)
Male gender (%) 63
BMI  (kg/m2) 23.6 (5.3)
PMADL-8 18.8 (5.7)
PeakVO2 (ml/min/kg) 18.1 (5.4)
VE/VCO2-slope 33.2 (9.9)
LVEF (%) 32.4 (8.2)
E/Ea 15.2 (9.7)
Plasma BNP (pg/ml) 222 (300)
Serum Na (mequiv./l) 139 (2.9)
Hb  (g/dl) 13.7 (1.8)
Alb  (g/dl) 3.9 (0.4)
e-GFR (ml/min/1.73 m2) 63.9 (25.4)
6MD  (m)  479 (102)
Medication n (%)
ACEi/ARB 78 (62.4)
Beta blockers 89 (71.5)
Diuretics 89 (71.5)
Digitalis 44 (35.2)
The data are presented as the mean (standard deviation).
BMI, body mass index; PMADL-8, Performance Measure for Activity of Daily
Living-8; peakVO2, peak oxygen uptake; VE/VCO2 slope, minute ventilation/carbon
dioxide production; LVEF, left ventricular ejection fraction; E/Ea, ratio of early
transmitral ﬂow velocity to early diastolic mitral annular velocity; BNP, brain
natriuretic peptide; serum Na, serum sodium; Hb, hemoglobin; Alb, albumin;
eGFR, estimated glomerular ﬁltration rate; 6MD, 6-min walking distance; ACEi,
angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor
blocker.
Table  2
The correlations between physiological and demographic variables and PMADL-8.
r p
Age 0.221 0.042
BMI  0.140 0.198
PeakVO2 −0.747 <0.001
VE/VCO2-slope 0.357 <0.001
LVEF −0.135 0.219
E/Ea 0.221 0.059
Hb  −0.325 0.002
Plasma BNP 0.205 0.067
Alb  −0.211 0.064
eGFR −0.093  0.483
6MD  −0.557 <0.001
Grip −0.319 0.007
Leg  strength −0.024 0.048
PMADL-8, Performance Measure for Activity of Daily Living-8; BMI, body mass
index; peakVO2, peak oxygen uptake; VE/VCO2 slope, minute ventilation/carbon
dioxide production; LVEF, left ventricular ejection fraction; E/Ea, ratio of early trans-
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Fig. 1. Correlation between PMADL-8 and peakVO2. PMADL-8 was  signiﬁcantly cor-
limitations in activity of daily living of CHF patients [7],  and the
study results demonstrate an excellent correlation with peakVO2
values that support assessment tool validity.
Table 3
Multivariate regression analysis results.
B SE B (95% CI) p
Min  Max
PeakVO2 −0.878 0.182 −4.581 −0.635 <0.001
34.31 3.230 <0.001
R = 0.635, R2 = 0.420, p < 0.001.
Estimated regression equation: PMALD-8 score = −0.878 × peakVO2 value + 34.31.
Dependent variable: PMADL-8.
Independent variables: age, peakVO2, VE/VCO2-slope, LVEF, E/Ea, Hb,  BNP, Alb, 6MD.itral ﬂow velocity to early diastolic mitral annular velocity; Hb: hemoglobin; BNP,
rain natriuretic peptide; Alb: albumin; eGFR, estimated glomerular ﬁltration rate;
nd 6MD, 6-min walking distance.
The correlations between the PMADL-8 score and the other
linical parameters are presented in Table 2 and Fig. 1. Age,
eakVO2, VE/VCO2-slope, hemoglobin, plasma BNP level, 6-min
alking distance, grip strength, and knee extensor muscle strength
ere signiﬁcantly correlated with PMADL-8 score, whereas LVEF
as not. The result of multivariate linear regression analysis
evealed that peakVO2 was an independently correlated factor of
he PMADL-8 score (r = 0.635, p < 0.001). An estimated regression
quation is displayed in Table 3. After calculations using this equa-
ion, the optimal PMALD-8 threshold predicting 18 ml/min/kg of
eakVO2 was 18 points. Similarly, a peakVO2 value at 14 ml/min/kg
as 22 points, and a peakVO2 value at 16 ml/min/kg was 20 points.iscussion
The main ﬁnding of this study was that, in stable CHF patients,
he PMADL-8 score was closely correlated to the peakVO2 value.related with peakVO2. PMADL-8, Performance Measure for Activity of Daily Living-8;
peakVO2, peak oxygen uptake.
The results of this study suggest that PMADL-8 is a useful assess-
ment tool for measuring disease severity in stable systolic HF
patients.
The results of this study clarify that the PMADL-8 score is a
valid assessment tool for measuring CHF disease severity, and
summary scores of 18 and 22 are meaningful thresholds for eval-
uating CHF disease severity. In previous research concerning CHF
disease-speciﬁc self-reporting questionnaires, such as the Kansas
City Cardiomyopathy Questionnaire and the Minnesota Living with
Heart Failure questionnaire, were developed for evaluating HRQOL
and included more than 20 items. Other questionnaires, such as the
Speciﬁc Activity Scale and the Left Ventricular Dysfunction 36, were
also developed for evaluating activity in CHF patients. These ques-
tionnaires evaluated the multidimensional aspects of CHF patients,
which included physical limitations, symptoms, self-efﬁcacy, and
social interference, and these questionnaires independently associ-
ated with cardiac events but were mildly to moderately correlated
with peakVO2 values (r = 0.3–0.6) [3,4,16–18].  In contrast, PMADL-
8 is a single-dimensional questionnaire that focuses on functionalPMADL-8, Performance Measure for Activity of Daily Living-8; peakVO2, peak oxy-
gen uptake; VE/VCO2 slope, minute ventilation/carbon dioxide production; LVEF,
left  ventricular ejection fraction; E/Ea, ratio of early transmitral ﬂow velocity to early
diastolic mitral annular velocity; Hb, hemoglobin; BNP, brain natriuretic peptide;
Alb,  albumin; 6MD, 6-min walking distance.
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The functional limitations in CHF primarily manifest from
linical symptoms, which are due to not only left ventricular
ysfunction but also systemic factors, such as skeletal muscle dys-
unction [5],  autonomic nervous system abnormalities [19] and
xcessive neurohormonal activation [6].  Even the main symptoms
f fatigability and dyspnea are hypothesized to be induced by skele-
al myopathy and muscle ergoreﬂex abnormalities [20]. Thus, the
unctional limitations described in PMADL-8 appear to reﬂect cen-
ral and systemic disease-speciﬁc abnormalities in CHF patients.
The ﬁndings of our study provide us the meanings of PMADL-
 score with CHF disease severity. The ﬁndings indicate that a
MADL-8 score of 18 reﬂects a peakVO2 value of 18 ml/min/kg;
imilarly, a PMADL-8 score of 22 reﬂects a peakVO2 value of
4 ml/min/kg. A peakVO2 value of 18 ml/min/kg was  suggested to
e a threshold for difﬁculty in ADL among community-dwelling
lderly people [21] and poor prognosis in CHF patients [22] and the
ealthy elderly [23]. A peakVO2 value of 14 ml/min/kg, which indi-
ated a very poor prognosis in CHF patients [22], has been applied
s a criterion for cardiac transplantation [1].  Speciﬁcally, a PMADL-
 score greater than 18 points indicated that the patient selected
 = somewhat hard for two  or more items and that the patient had
egun to feel some difﬁculty in daily life. Because atrial ﬁbrilla-
ion (Af) is one confounding factor of echocardiography ﬁndings,
atients with Af were excluded in this study. However, we  also
onﬁrmed that there was a good correlation between PMADL-8 and
eakVO2 in another group of 18 patients with chronic Af (r = −0.733,
 < 0.001, data not shown). Therefore, PMADL-8 may  be also useful
or HF patients with Af.
ACC/AHA guidelines [1] provide few tools for monitoring CHF
atients. Although many clinical markers, such as echocardiogra-
hy, electrocardiography, hemodynamic status, biochemical and
xercise testing, have been provided for CHF risk stratiﬁcation,
ome of these tend to be invasive, complicated to obtain, and
ostly. In contrast, PMADL-8 is simple to administrate and score,
s noninvasive, and can be administrated repeatedly at a low cost.
MADL-8 may  have an important role in clinical research and dis-
ase management programs in which follow-up and care need to
e efﬁciently provided for an entire population of CHF patients.
This study has potential limitations. Our patients had mild to
oderate CHF, and it remains unclear whether PMADL is also cor-
elated with peakVO2 among patients with moderate to severe CHF.
owever, it is contraindicated to perform CPX in CHF patients with
HYA class IV, so PMADL-8 may  serve as meaningful information
n CHF outpatients. This study was determined by cross-sectional
ssessment, therefore, we cannot describe the association between
hanges in PMADL-8 and changes in peakVO2, so further research
s needed to conﬁrm the responsiveness of PMADL-8. Further-
ore, the association PMADL-8 score and clinical hard endpoints
lso remain unclear. These shortcomings will be addressed by the
esults of our ongoing, prospective study “PTMaTCH” (Preventive
ffect of exercise for management of daily functioning in patients
ith CHF: a rehabilitation cohort study) in which we  will ana-
yze the relationship between the time between the PMADL-8
ssessment after discharge and rehospitalization in CHF patients
ho were hospitalized due to an acute exacerbation. Neverthe-
ess, the results of the present study provide novel information that
unctional limitation will be a possible clinical assessment tool to
etermine disease severity in CHF patients. Further study will be
equired to investigate the responsiveness of PMADL-8 in high-risk
HF patients.onclusions
The ﬁndings of the present study indicate that the PMADL-8
core is closely correlated with peak oxygen uptake. PMADL-8 is
[logy 60 (2012) 411–415
a simple and inexpensive tool for evaluating functional limitation
and may  provide a meaningful outcome in cardiovascular rehabili-
tation as well as clinical epidemiological research for patients with
CHF.
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Appendix A.
Performance Measure for Activities of Daily Living-8 (PMADL-8)
1 = very easy; 2 = somewhat easy; 3 = somewhat hard; and 4 = very hard
1. Getting up and off from the ﬂoor without tools
2. Washing your body and hair
3. Walking upstairs without a handrail
4.  Vacuuming your room
5. Pulling and closing a heavy sliding door
6.  Getting into and out of a car
7. Walking at the same speed with someone of the same age
8. Walking up a slight slope for 10 min
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